PL1756084T3 - Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto - Google Patents
Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related theretoInfo
- Publication number
- PL1756084T3 PL1756084T3 PL05755596T PL05755596T PL1756084T3 PL 1756084 T3 PL1756084 T3 PL 1756084T3 PL 05755596 T PL05755596 T PL 05755596T PL 05755596 T PL05755596 T PL 05755596T PL 1756084 T3 PL1756084 T3 PL 1756084T3
- Authority
- PL
- Poland
- Prior art keywords
- prophylaxis
- modulators
- metabolism
- treatment
- substituted aryl
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 208000035475 disorder Diseases 0.000 title 1
- 125000001072 heteroaryl group Chemical group 0.000 title 1
- 230000004060 metabolic process Effects 0.000 title 1
- 238000011321 prophylaxis Methods 0.000 title 1
- 125000003107 substituted aryl group Chemical group 0.000 title 1
- 238000011282 treatment Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57735404P | 2004-06-04 | 2004-06-04 | |
| EP05755596A EP1756084B1 (en) | 2004-06-04 | 2005-06-02 | Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
| PCT/US2005/019318 WO2005121121A2 (en) | 2004-06-04 | 2005-06-02 | Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1756084T3 true PL1756084T3 (en) | 2009-06-30 |
Family
ID=34971499
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL05755596T PL1756084T3 (en) | 2004-06-04 | 2005-06-02 | Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US20090036434A1 (en) |
| EP (1) | EP1756084B1 (en) |
| JP (1) | JP2008501698A (en) |
| CN (2) | CN101870690A (en) |
| AR (1) | AR049293A1 (en) |
| AT (1) | ATE415397T1 (en) |
| AU (1) | AU2005252211A1 (en) |
| BR (1) | BRPI0511757A (en) |
| CA (1) | CA2568451A1 (en) |
| CR (1) | CR8741A (en) |
| CY (1) | CY1108762T1 (en) |
| DE (1) | DE602005011279D1 (en) |
| DK (1) | DK1756084T3 (en) |
| EA (1) | EA011671B1 (en) |
| EC (1) | ECSP067066A (en) |
| ES (1) | ES2320359T3 (en) |
| HR (1) | HRP20090093T3 (en) |
| IL (1) | IL179458A (en) |
| MX (1) | MXPA06014129A (en) |
| NO (1) | NO20065868L (en) |
| NZ (1) | NZ552387A (en) |
| PE (1) | PE20060530A1 (en) |
| PL (1) | PL1756084T3 (en) |
| PT (1) | PT1756084E (en) |
| RS (1) | RS50755B (en) |
| SI (1) | SI1756084T1 (en) |
| TW (1) | TW200610528A (en) |
| UA (1) | UA92150C2 (en) |
| WO (1) | WO2005121121A2 (en) |
| ZA (1) | ZA200610095B (en) |
Families Citing this family (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20050696B1 (en) | 2003-01-14 | 2008-10-31 | Arena Pharmaceuticals Inc. | 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia |
| AR045047A1 (en) | 2003-07-11 | 2005-10-12 | Arena Pharm Inc | ARILO AND HETEROARILO DERIVATIVES TRISUSTITUIDOS AS MODULATORS OF METABOLISM AND PROFILAXIS AND TREATMENT OF DISORDERS RELATED TO THEMSELVES |
| US7132426B2 (en) | 2003-07-14 | 2006-11-07 | Arena Pharmaceuticals, Inc. | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
| MX2007007553A (en) * | 2004-12-24 | 2007-08-15 | Prosidion Ltd | G-protein coupled receptor (gpr116) agonists and use thereof for treating obesity and diabetes. |
| DOP2006000008A (en) * | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | COMBINED THERAPY FOR THE TREATMENT OF DIABETES AND RELATED AFFECTIONS AND FOR THE TREATMENT OF AFFECTIONS THAT IMPROVE THROUGH AN INCREASE IN THE BLOOD CONCENTRATION OF GLP-1 |
| MY148521A (en) | 2005-01-10 | 2013-04-30 | Arena Pharm Inc | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto |
| EP1902051A1 (en) * | 2005-06-09 | 2008-03-26 | Merck Frosst Canada Ltd. | Azacyclohexane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| JP2008545009A (en) * | 2005-06-30 | 2008-12-11 | プロシディオン・リミテッド | GPCR agonist |
| ATE429430T1 (en) * | 2005-09-16 | 2009-05-15 | Arena Pharm Inc | METABOLIC MODULATORS AND TREATMENT OF ASSOCIATED DISEASES |
| DE602007010420D1 (en) | 2006-04-11 | 2010-12-23 | Arena Pharm Inc | METHOD OF USE OF THE GPR119 RECEPTOR FOR IDENTIFYING COMPOUNDS FOR INCREASING THE BONE MASS IN ONE PERSON |
| PE20071221A1 (en) * | 2006-04-11 | 2007-12-14 | Arena Pharm Inc | GPR119 RECEPTOR AGONISTS IN METHODS TO INCREASE BONE MASS AND TO TREAT OSTEOPOROSIS AND OTHER CONDITIONS CHARACTERIZED BY LOW BONE MASS, AND COMBINED THERAPY RELATED TO THESE AGONISTS |
| TW200811147A (en) * | 2006-07-06 | 2008-03-01 | Arena Pharm Inc | Modulators of metabolism and the treatment of disorders related thereto |
| TW200811140A (en) * | 2006-07-06 | 2008-03-01 | Arena Pharm Inc | Modulators of metabolism and the treatment of disorders related thereto |
| US20080103141A1 (en) * | 2006-08-30 | 2008-05-01 | Biovitrum | New compounds |
| DK2076508T3 (en) | 2006-10-18 | 2011-02-21 | Pfizer Prod Inc | The biaryl ether urea compounds |
| EP2094683B1 (en) | 2006-12-06 | 2011-10-12 | GlaxoSmithKline LLC | Bicyclic compounds and use as antidiabetics |
| JP4782239B2 (en) | 2007-04-18 | 2011-09-28 | ファイザー・プロダクツ・インク | Sulfonylamide derivatives for the treatment of abnormal cell proliferation |
| US7910583B2 (en) | 2007-05-04 | 2011-03-22 | Bristol-Myers Squibb Company | [6,6] and [6,7]-bicyclic GPR119 G protein-coupled receptor agonists |
| JP2010526146A (en) | 2007-05-04 | 2010-07-29 | ブリストル−マイヤーズ スクイブ カンパニー | [6,5] -bicyclic GPR119G protein-coupled receptor agonist |
| US7928230B2 (en) | 2007-07-17 | 2011-04-19 | Bristol-Myers Squibb Company | Method for modulating GPR119 G protein-coupled receptor and selected compounds |
| BRPI0817211A2 (en) | 2007-09-20 | 2017-05-16 | Irm Llc | compound compositions as modulators of gpr119 activity |
| NZ585284A (en) * | 2007-10-16 | 2011-03-31 | Daiichi Sankyo Co Ltd | Pyrimidyl indoline compounds with hypoglycaemic effect useful in the treatment of diabetes related diseases and adiposity |
| AU2008317057B8 (en) | 2007-10-22 | 2014-02-13 | Merck Sharp & Dohme Corp. | Bicyclic Heterocycle Derivatives and their use as modulators of the activity of GPR119 |
| WO2009063364A2 (en) * | 2007-11-13 | 2009-05-22 | Encysive Pharmaceuticals Inc. | Modulators of urotensin receptor and methods of use thereof |
| AU2009217359B2 (en) * | 2008-02-22 | 2011-09-01 | Irm Llc | Compounds and compositions as modulators of GPR119 activity |
| EP2146210A1 (en) | 2008-04-07 | 2010-01-20 | Arena Pharmaceuticals, Inc. | Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY |
| US8343990B2 (en) | 2008-04-14 | 2013-01-01 | Merck Sharp & Dohme Corp. | Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment |
| TW201006821A (en) * | 2008-07-16 | 2010-02-16 | Bristol Myers Squibb Co | Pyridone and pyridazone analogues as GPR119 modulators |
| WO2010048149A2 (en) * | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
| WO2010059384A1 (en) * | 2008-10-30 | 2010-05-27 | Janssen Pharmaceutica Nv | Process for the preparation of tri-substituted pyridine and tri-substituted pyrimidine derivatives useful as gdir agonists |
| AU2009330208A1 (en) | 2008-12-23 | 2011-08-04 | Merck Sharp & Dohme Corp. | Bicyclic heterocycle derivatives and methods of use thereof |
| EP2382204B1 (en) | 2008-12-23 | 2018-07-11 | Merck Sharp & Dohme Corp. | Pyrimidine derivatives as gpcr modulators for use in the treatment of obesity and diabetes |
| CA2749931C (en) * | 2009-01-26 | 2018-03-06 | Taipei Medical University | Use of pterosin compounds for treating diabetes and obesity |
| WO2010095663A1 (en) * | 2009-02-18 | 2010-08-26 | 武田薬品工業株式会社 | Fused heterocyclic ring compound |
| JP2012520868A (en) * | 2009-03-20 | 2012-09-10 | ファイザー・インク | 3-Oxa-7-azabicyclo [3.3.1] nonane |
| EP2414348B1 (en) | 2009-04-03 | 2013-11-20 | Merck Sharp & Dohme Corp. | Bicyclic piperidine and piperazine derivatives as gpcr modulators for the treatment of obesity, diabetes and other metabolic disorders |
| WO2010119881A1 (en) * | 2009-04-15 | 2010-10-21 | 第一三共株式会社 | Indoline compound |
| TW201113269A (en) | 2009-06-24 | 2011-04-16 | Boehringer Ingelheim Int | New compounds, pharmaceutical composition and methods relating thereto |
| BR112012000831A2 (en) | 2009-06-24 | 2019-09-24 | Boehringer Ingelheim Int | related compounds, pharmaceutical compositions and methods |
| WO2011019538A1 (en) | 2009-08-13 | 2011-02-17 | Merck Sharp & Dohme Corp. | Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment |
| US20120295845A1 (en) * | 2009-11-23 | 2012-11-22 | Pfizer Inc | Imidazo-pyrazoles as gpr119 inhibitors |
| SG182610A1 (en) | 2010-01-27 | 2012-08-30 | Arena Pharm Inc | Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof |
| JP2013522279A (en) | 2010-03-18 | 2013-06-13 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Combination of GPR119 agonist and DDP-IV inhibitor linagliptin for use in the treatment of diabetes and related conditions |
| JP2013523822A (en) | 2010-04-08 | 2013-06-17 | ブリストル−マイヤーズ スクイブ カンパニー | Pyrimidinyl piperidinyloxypyridino analogues as GPR119 modifiers |
| EP2566860B1 (en) | 2010-05-06 | 2014-09-10 | Bristol-Myers Squibb Company | Bicyclic heteroaryl compounds as gpr119 modulators |
| EP2566862B1 (en) | 2010-05-06 | 2015-09-16 | Bristol-Myers Squibb Company | Benzofuranyl analogues as gpr119 modulators |
| BR112012029395A2 (en) | 2010-05-17 | 2016-07-26 | Array Biopharma Inc | piperdinyl-substituted lactams as gpr119 modulators |
| WO2012025811A1 (en) | 2010-08-23 | 2012-03-01 | Lupin Limited | Indolylpyrimidines as modulators of gpr119 |
| MX2013003184A (en) * | 2010-09-22 | 2013-06-07 | Arena Pharm Inc | Modulators of the gpr119 receptor and the treatment of disorders related thereto. |
| JO3145B1 (en) | 2010-11-08 | 2017-09-20 | Lilly Co Eli | Compounds useful for inhibiting chk1 |
| EP2643311A1 (en) | 2010-11-26 | 2013-10-02 | Lupin Limited | Bicyclic gpr119 modulators |
| AU2012267556B9 (en) | 2011-06-09 | 2017-05-11 | Rhizen Pharmaceuticals Sa | Novel compounds as modulators of GPR-119 |
| CA2841757A1 (en) | 2011-07-15 | 2013-01-24 | Etzer Darout | Gpr 119 modulators |
| WO2013066869A1 (en) * | 2011-11-03 | 2013-05-10 | Array Biopharma Inc. | Piperidinyl-substituted lactams as gpr119 modulators |
| CN104024246B (en) * | 2012-03-27 | 2016-03-02 | 广东东阳光药业有限公司 | As the substituted pyrimidines derivative of Ou Ruola kinase inhibitor |
| EP2841428B1 (en) | 2012-04-24 | 2018-08-22 | Vertex Pharmaceuticals Incorporated | Dna-pk inhibitors |
| EP2850073B1 (en) | 2012-05-16 | 2017-07-19 | Bristol-Myers Squibb Company | Pyrimidinylpiperidinyloxypyridone analogues as gpr119 modulators |
| WO2014159690A1 (en) | 2013-03-12 | 2014-10-02 | Vertex Pharmaceuticals Incorporated | Dna-pk inhibitors |
| GB2516303A (en) * | 2013-07-18 | 2015-01-21 | Redx Pharma Ltd | Compounds |
| PL3424920T3 (en) | 2013-10-17 | 2020-11-16 | Vertex Pharmaceuticals Incorporated | Co-crystals of (s)-n-methyl-8-(1-((2'-methyl-[4,5'-bipyrimidin]-6-yl)amino)propan-2-yl)quinoline-4-carboxamide and deuterated derivatives thereof as dna-pk inhibitors |
| AR098394A1 (en) * | 2013-11-25 | 2016-05-26 | Lilly Co Eli | DGAT2 INHIBITORS (DIACILGLICEROL O-ACILTRANSFERASA 2) |
| SG11201700777VA (en) * | 2014-08-04 | 2017-02-27 | Nuevolution As | Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases |
| US11007175B2 (en) | 2015-01-06 | 2021-05-18 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the S1P1 receptor |
| BR112017027656B1 (en) | 2015-06-22 | 2023-12-05 | Arena Pharmaceuticals, Inc. | CRYSTALLINE HABIT OF SALT-FREE PLATE OF ACID L-ARGININE (R)-2-(7-(4- CYCLOPENTYL-3-(TRIFLUOROMETHYL)BENZYLOXY)- 1,2,3,4-TETRA-HYDROCYCLO-PENTA[B ]INDOL-3- IL)ACETIC, PHARMACEUTICAL COMPOSITION THAT COMPRISES IT, ITS USES AND METHOD OF PREPARATION THEREOF |
| GB201514021D0 (en) | 2015-08-07 | 2015-09-23 | Arner Elias Set Jeno | Novel Pyridines and their use in the treatment of cancer |
| WO2017121700A1 (en) | 2016-01-15 | 2017-07-20 | Bayer Pharma Aktiengesellschaft | 1,3-disubstituted 1h-pyrazolo[3,4-b]pyridine derivatives and use thereof as stimulators of soluble guanylate cyclase |
| EP3468967B1 (en) | 2016-06-09 | 2023-07-26 | Pramana Pharmaceuticals Inc. | Compounds containing benzo[d][1,3]oxathiole, benzo[d][1,3]oxathiole 3-oxide or benzo[d][1,3]oxathiole 3,3-dioxide and methods/uses thereof as agonists of g protein-coupled receptor 119 |
| WO2018064092A1 (en) | 2016-09-27 | 2018-04-05 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of dna-damaging agents and dna-pk inhibitors |
| AU2018218519B2 (en) | 2017-02-07 | 2021-08-05 | Oblique Therapeutics Ab | Heteroarylsulfonyl-substituted pyridines and their use in the treatment of cancer |
| EP3580204A1 (en) | 2017-02-07 | 2019-12-18 | Oblique Therapeutics AB | Sulfinylpyridines and their use in the treatment of cancer |
| JP7229176B2 (en) | 2017-02-07 | 2023-02-27 | オブリーク セラピューティクス アーベー | Hydrocarbylsulfonyl-substituted pyridines and their use in treating cancer |
| MA47452A (en) | 2017-02-07 | 2019-12-18 | Oblique Therapeutics Ab | HETEROCYCLYLSULFONYL SUBSTITUTION PYRIDINES AND THEIR USE IN CANCER TREATMENT |
| CA3053418A1 (en) | 2017-02-16 | 2018-08-23 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of primary biliary cholangitis |
| EP3615529B1 (en) | 2017-04-26 | 2024-06-05 | Basilea Pharmaceutica International AG, Allschwil | Processes for the preparation of furazanobenzimidazoles and crystalline forms thereof |
| WO2018236896A1 (en) | 2017-06-19 | 2018-12-27 | Arena Pharmaceuticals, Inc. | COMPOUNDS AND METHODS FOR THE TREATMENT OF NAFLD AND NASH |
| US11358956B2 (en) | 2017-11-30 | 2022-06-14 | Pramana Pharmaceuticals Inc. | Compounds containing polysubstituted benzo[d][1,3]oxathiole, benzo[d][1,3]oxathiole 3-oxide or benzo[d][1,3]oxathiole 3,3-dioxide and methods/uses thereof as agonists of G protein-coupled receptor 119 |
| BR112020024762A2 (en) | 2018-06-06 | 2021-03-23 | Arena Pharmaceuticals, Inc. | methods of treating conditions related to the s1p1 receptor |
| PL3966206T3 (en) | 2019-05-10 | 2024-01-29 | Deciphera Pharmaceuticals, Llc | Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof |
| HUE065486T2 (en) | 2019-05-10 | 2024-05-28 | Deciphera Pharmaceuticals Llc | Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof |
| AU2020297422B2 (en) | 2019-06-17 | 2024-03-21 | Deciphera Pharmaceuticals, Llc | Aminopyrimidine amide autophagy inhibitors and methods of use thereof |
| EP4076661A1 (en) * | 2019-12-20 | 2022-10-26 | Nuevolution A/S | Compounds active towards nuclear receptors |
| EP4076657A1 (en) | 2019-12-20 | 2022-10-26 | Nuevolution A/S | Compounds active towards nuclear receptors |
| WO2021198955A1 (en) * | 2020-03-31 | 2021-10-07 | Nuevolution A/S | Compounds active towards nuclear receptors |
| EP4126875A1 (en) * | 2020-03-31 | 2023-02-08 | Nuevolution A/S | Compounds active towards nuclear receptors |
| WO2023107705A1 (en) | 2021-12-10 | 2023-06-15 | Incyte Corporation | Bicyclic amines as cdk12 inhibitors |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH478817A (en) * | 1965-10-22 | 1969-09-30 | Ciba Geigy | Process for the preparation of new N, N'-di- (pyrimidyl- (4) -aminoalkyl) -diazacycloalkanes |
| CH480410A (en) * | 1967-01-09 | 1969-10-31 | Geigy Ag J R | Process for the preparation of water-soluble azopyrimidine dyes |
| CA961052A (en) * | 1967-01-12 | 1975-01-14 | Max Schellenbaum | N-2-ethylhexyl-n'-aryl ureas and preparation containing them |
| US3608087A (en) * | 1968-06-21 | 1971-09-21 | Merck & Co Inc | Feed compositions |
| US3887329A (en) * | 1969-05-05 | 1975-06-03 | Ciba Geigy Ag | Hexamethyl phosphotriamide-dye compositions |
| US3686238A (en) * | 1970-01-19 | 1972-08-22 | Syntex Corp | Glycerol esterified with 2-naphthyl-acetic acids and fatty acids |
| US3852434A (en) * | 1970-09-11 | 1974-12-03 | Merck & Co Inc | Potentiation of ({31 ) cis-1,2-epoxypropyl)phosphonic acid and analogues thereof |
| US3966744A (en) * | 1971-01-11 | 1976-06-29 | Syva Company | Spin labeled compounds |
| US3690834A (en) * | 1971-01-11 | 1972-09-12 | Syva Co | Ligand determination with spin labeled compounds by receptor displacement |
| DE2106585A1 (en) * | 1971-02-11 | 1972-08-24 | Farbenfabriken Bayer Ag, 5090 Leverkusen | Aminothiodiazoles and thiodiazole azo dyes |
| US3966764A (en) * | 1972-07-10 | 1976-06-29 | Syva Company | Ligand determination of spin labeled compounds by receptor displacement-amphetamine analogs |
| US3849420A (en) * | 1972-10-20 | 1974-11-19 | Dow Chemical Co | Bis-(alkylthio-and alkylsulfonyl)-pentachloroquinolines |
| CH574206A5 (en) * | 1972-11-16 | 1976-04-15 | Ciba Geigy Ag | |
| DE2340569C2 (en) * | 1973-08-10 | 1982-12-02 | Bayer Ag, 5090 Leverkusen | Azo dyes |
| AT340933B (en) * | 1973-08-20 | 1978-01-10 | Thomae Gmbh Dr K | PROCESS FOR THE PRODUCTION OF NEW PYRIMIDE DERIVATIVES AND THEIR ACID ADDITIONAL SALTS |
| US4101541A (en) * | 1973-12-21 | 1978-07-18 | Ciba-Geigy Corporation | 3-Cyano-1,2,4-thiadiazolyl-5-czo dyestuffs |
| FR2306697A1 (en) * | 1975-04-10 | 1976-11-05 | Sogeras | NEW PYRIMIDINES FOR USE AS ANTIDIABETIC AND HYPOCHOLESTEROLEMANT MEDICINAL PRODUCTS |
| DE2731264A1 (en) * | 1977-07-11 | 1979-02-01 | Boehringer Mannheim Gmbh | NEW 1-ACYL-2-CYANAZIRIDINE, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING THESE COMPOUNDS |
| JPS6038696B2 (en) * | 1977-12-09 | 1985-09-02 | コニカ株式会社 | Silver halide color photographic material |
| US4242507A (en) * | 1978-02-23 | 1980-12-30 | Fujisawa Pharmaceutical Co., Ltd. | Sulfonic acid esters |
| DE2831580C2 (en) * | 1978-07-18 | 1980-09-18 | Boehringer Mannheim Gmbh, 6800 Mannheim | Method and reagent for the determination of glycerin |
| DE2906603A1 (en) * | 1979-02-21 | 1980-09-04 | Boehringer Mannheim Gmbh | N-SUBSTITUTED AZIRIDINE-2-CARBONIC ACID DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE SUBSTANCES |
| DOP1981004033A (en) * | 1980-12-23 | 1990-12-29 | Ciba Geigy Ag | PROCEDURE TO PROTECT CROP PLANTS FROM PHYTOTOXIC ACTION OF HERBICIDES. |
| DE3334455A1 (en) * | 1983-03-04 | 1984-09-06 | Bayer Ag, 5090 Leverkusen | GUANIDIN DERIVATIVES |
| ZA848275B (en) * | 1983-12-28 | 1985-08-28 | Degussa | New piridine-2-ethers or pyridine-2-thioethers having a nitrogen-containing cycloaliphatic ring |
| DE3601196A1 (en) * | 1986-01-17 | 1987-07-23 | Merck Patent Gmbh | 1,4-DIHYDROPYRIDINE |
| TW574214B (en) * | 1994-06-08 | 2004-02-01 | Pfizer | Corticotropin releasing factor antagonists |
| PT781766E (en) * | 1994-09-09 | 2004-07-30 | Nippon Shinyaku Co Ltd | HETEROCYLIC DERIVATIVES AND MEDICINAL PRODUCTS |
| US5691364A (en) * | 1995-03-10 | 1997-11-25 | Berlex Laboratories, Inc. | Benzamidine derivatives and their use as anti-coagulants |
| US6403599B1 (en) * | 1995-11-08 | 2002-06-11 | Pfizer Inc | Corticotropin releasing factor antagonists |
| US6956047B1 (en) * | 1995-06-06 | 2005-10-18 | Pfizer Inc. | Corticotropin releasing factor antagonists |
| US5849759A (en) * | 1995-12-08 | 1998-12-15 | Berlex Laboratories, Inc. | Naphthyl-substituted benzimidazole derivatives as anti-coagulants |
| US5948786A (en) * | 1996-04-12 | 1999-09-07 | Sumitomo Pharmaceuticals Company, Limited | Piperidinylpyrimidine derivatives |
| AR008789A1 (en) * | 1996-07-31 | 2000-02-23 | Bayer Corp | PIRIDINES AND SUBSTITUTED BIPHENYLS |
| US6008234A (en) * | 1996-09-12 | 1999-12-28 | Berlex Laboratories, Inc. | Benzamidine derivatives substituted by cyclic amino acid and cyclic hydroxy acid derivatives and their use as anti-coagulants |
| EP1054005A4 (en) * | 1998-02-05 | 2003-02-05 | Takeda Chemical Industries Ltd | SULFAMIDE DERIVATIVES, THEIR PRODUCTION PROCESS AND THEIR USE |
| US6187777B1 (en) * | 1998-02-06 | 2001-02-13 | Amgen Inc. | Compounds and methods which modulate feeding behavior and related diseases |
| US6239126B1 (en) * | 1998-12-17 | 2001-05-29 | American Home Products Corporation | Arylpiperidine and aryl-1,2,5,6-tetra-hydropyridine urea derivatives |
| ATE309241T1 (en) * | 1999-09-10 | 2005-11-15 | Merck & Co Inc | TYROSINE KINASE INHIBITORS |
| US6414002B1 (en) * | 1999-09-22 | 2002-07-02 | Bristol-Myers Squibb Company | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
| US20020137755A1 (en) * | 2000-12-04 | 2002-09-26 | Bilodeau Mark T. | Tyrosine kinase inhibitors |
| US6545016B1 (en) * | 2000-12-08 | 2003-04-08 | 3M Innovative Properties Company | Amide substituted imidazopyridines |
| US6525064B1 (en) * | 2000-12-08 | 2003-02-25 | 3M Innovative Properties Company | Sulfonamido substituted imidazopyridines |
| US6545017B1 (en) * | 2000-12-08 | 2003-04-08 | 3M Innovative Properties Company | Urea substituted imidazopyridines |
| US6825198B2 (en) * | 2001-06-21 | 2004-11-30 | Pfizer Inc | 5-HT receptor ligands and uses thereof |
| CA2450562A1 (en) * | 2001-06-22 | 2003-01-03 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| JP4510442B2 (en) * | 2001-06-26 | 2010-07-21 | ブリストル−マイヤーズ スクイブ カンパニー | N-heterocyclic inhibitor of TNF-α expression |
| EP1558609A4 (en) * | 2002-10-30 | 2008-05-28 | Merck & Co Inc | Kinase inhibitors |
| HRP20050696B1 (en) * | 2003-01-14 | 2008-10-31 | Arena Pharmaceuticals Inc. | 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia |
| WO2004078114A2 (en) * | 2003-02-28 | 2004-09-16 | Encysive Pharmaceuticals Inc. | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-ii receptor antagonists. |
| US7083933B1 (en) * | 2003-05-09 | 2006-08-01 | Prosidion Limited | Methods for identification of modulators of OSGPR116 activity |
| AR045047A1 (en) * | 2003-07-11 | 2005-10-12 | Arena Pharm Inc | ARILO AND HETEROARILO DERIVATIVES TRISUSTITUIDOS AS MODULATORS OF METABOLISM AND PROFILAXIS AND TREATMENT OF DISORDERS RELATED TO THEMSELVES |
| MXPA06003615A (en) * | 2003-09-30 | 2006-06-05 | Amgen Inc | Vanilloid receptor ligands and their use in treatments. |
| AU2005212438A1 (en) * | 2004-02-11 | 2005-08-25 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
| MY148521A (en) * | 2005-01-10 | 2013-04-30 | Arena Pharm Inc | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto |
-
2005
- 2005-06-02 UA UAA200613592A patent/UA92150C2/en unknown
- 2005-06-02 PL PL05755596T patent/PL1756084T3/en unknown
- 2005-06-02 DK DK05755596T patent/DK1756084T3/en active
- 2005-06-02 PT PT05755596T patent/PT1756084E/en unknown
- 2005-06-02 CN CN201010134583A patent/CN101870690A/en active Pending
- 2005-06-02 NZ NZ552387A patent/NZ552387A/en unknown
- 2005-06-02 EP EP05755596A patent/EP1756084B1/en not_active Expired - Lifetime
- 2005-06-02 CA CA002568451A patent/CA2568451A1/en not_active Abandoned
- 2005-06-02 JP JP2007515543A patent/JP2008501698A/en active Pending
- 2005-06-02 DE DE602005011279T patent/DE602005011279D1/en not_active Expired - Lifetime
- 2005-06-02 AT AT05755596T patent/ATE415397T1/en active
- 2005-06-02 HR HR20090093T patent/HRP20090093T3/en unknown
- 2005-06-02 BR BRPI0511757-7A patent/BRPI0511757A/en not_active IP Right Cessation
- 2005-06-02 EA EA200602179A patent/EA011671B1/en not_active IP Right Cessation
- 2005-06-02 MX MXPA06014129A patent/MXPA06014129A/en active IP Right Grant
- 2005-06-02 PE PE2005000621A patent/PE20060530A1/en not_active Application Discontinuation
- 2005-06-02 US US11/628,408 patent/US20090036434A1/en not_active Abandoned
- 2005-06-02 RS RSP-2009/0065A patent/RS50755B/en unknown
- 2005-06-02 WO PCT/US2005/019318 patent/WO2005121121A2/en not_active Ceased
- 2005-06-02 CN CNA2005800178342A patent/CN1997640A/en active Pending
- 2005-06-02 SI SI200530587T patent/SI1756084T1/en unknown
- 2005-06-02 ES ES05755596T patent/ES2320359T3/en not_active Expired - Lifetime
- 2005-06-02 AU AU2005252211A patent/AU2005252211A1/en not_active Abandoned
- 2005-06-03 AR ARP050102283A patent/AR049293A1/en not_active Application Discontinuation
- 2005-06-03 TW TW094118499A patent/TW200610528A/en unknown
-
2006
- 2006-11-09 CR CR8741A patent/CR8741A/en unknown
- 2006-11-21 IL IL179458A patent/IL179458A/en not_active IP Right Cessation
- 2006-12-01 ZA ZA200610095A patent/ZA200610095B/en unknown
- 2006-12-04 EC EC2006007066A patent/ECSP067066A/en unknown
- 2006-12-19 NO NO20065868A patent/NO20065868L/en not_active Application Discontinuation
-
2009
- 2009-02-12 CY CY20091100157T patent/CY1108762T1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL179458A0 (en) | Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | |
| IL172567A0 (en) | Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | |
| IL172621A0 (en) | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | |
| IL184363A0 (en) | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto | |
| ZA200607433B (en) | Methods and compositions for the treatment of gastroin-testinal disorders | |
| IL195819A0 (en) | Modulators of metabolism and the treatment of disorders related thereto | |
| IL195851A0 (en) | Modulators of metabolism and the treatment of disorders related thereto | |
| IL179508A0 (en) | 2-substituted-4- heteroaryl-pyrimidines useful for the treatment of proliferative disorders | |
| AP2007004031A0 (en) | Novel heterocyclic compounds useful for the treatment of inflamatory and allergic disorders | |
| IL177772A0 (en) | Methods and compositions for the treatment of gastrointestinal disorders | |
| EP1893216A4 (en) | Methods and compositions for the treatment of ocular disorders | |
| EP1853295A4 (en) | Methods and compositions for the treatment of gastrointestinal disorders | |
| EP1940441A4 (en) | Methods and compositions for the treatment of gastrointestinal disorders | |
| IL195906A0 (en) | Alpha-aminoamide derivatives useful in the treatment of cognitive disorders | |
| AP2007004157A0 (en) | N- (N-sulfonylaminomethyl) cyclo-propanecarboxamide derivatives useful for the treatment of pain | |
| IL189009A0 (en) | Methods and compositions for the treatment of neuropathies and related disorders | |
| SI2024368T1 (en) | 6,7,8,9-tetrahydro-5h-pyrimidoš4,5-dćazepin-4-ylć-amine derivatives as modulators of trpv1 for the treatment of pain | |
| PL1890684T3 (en) | Treatment of sleep-wake disorders | |
| IL191537A0 (en) | Methods and compositions for the treatment of gastrointestinal disorders | |
| SI1831227T1 (en) | Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders | |
| PL1959957T3 (en) | Pyrimidylaminobenzamide derivatives for the treatment of neurofibromatosis | |
| SG144942A1 (en) | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | |
| HK1083099A (en) | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | |
| ZA200805859B (en) | Methods and compositions for the treatment of gastriontestinal disorders | |
| HK1141282A (en) | Bicyclic aryl and heteroaryl compounds for the treatment of metabolic disorders |